Related Experiment Videos
[Benzodiazepines and pregnancy]
M C Pérault1, S Favrelière, P Minet
1Service de Pharmacologie Clinique, CRPV, CHU La Milétrie, 350 avenue Jacques Coeur BP 577, 86021 Poitiers, France.
Therapie
|February 24, 2001
Summary
Benzodiazepine use during pregnancy poses minimal risk for fetal malformations. However, prolonged exposure, especially to long-acting types, may cause neonatal issues like hypotonicity and withdrawal symptoms.
Area of Science:
- Pharmacology
- Teratology
- Neonatal Medicine
Background:
- Benzodiazepine prescriptions are common among pregnant women, with self-medication being a significant factor.
- Understanding the potential fetal impacts of maternal benzodiazepine use is crucial for prenatal care.
Purpose of the Study:
- To evaluate the effects of benzodiazepine exposure on the fetus during pregnancy.
- To synthesize findings from animal studies, clinical data, and pharmacovigilance observations.
Main Methods:
- A comprehensive review of existing animal and clinical studies was conducted.
- Data from Centres Régionaux de Pharmacovigilance (CRPV) observations were incorporated.
- Pooled analysis of available research was performed to assess risks.
Main Results:
- The risk of congenital malformations from first-trimester benzodiazepine exposure appears to be low.
- Neonatal complications, including hypotonicity, feeding difficulties, and withdrawal syndrome, were observed in cases of long-term, particularly long-acting benzodiazepine exposure.
Conclusions:
- While first-trimester benzodiazepine exposure carries a small risk of malformations, prolonged exposure presents risks for neonatal adaptation.
- Careful consideration and monitoring are warranted for pregnant women using benzodiazepines, especially long-acting formulations.